CVS monthly performance report
Explore CVS's monthly returns, drawdown, and seasonality trends — updated every month.
CVS monthly report
—
Key takeaways
- CVS Health (CVS) closed September 2026 at $90.27, down 3.88% for the month and +21.99% over the trailing 12 months.
- Year-to-date, CVS is +13.75%, outperforming the S&P 500 which has returned +11.83% YTD.
- The stock is trading +4.01% versus its 200-day moving average ($86.79), a bullish technical signal.
- Over the past three years, CVS has underperformed the S&P 500 by −44.63%, with a relative strength index reading of 74.3.
- Win rate over the trailing 39 months stands at 51.3% — 20 positive months versus 18 negative months.
CVS Health ended September 2026 at $90.27, posting a monthly return of −3.88%. The S&P 500 returned −0.58% over the same window, leaving relative performance at −3.30%.
The current quarter stands at −12.74% (Q3 2026 (QTD)), while medium-term trend remains constructive: price is +4.01% versus the 200-day moving average ($86.79).
Year-to-date, CVS is +13.75% against SPY +11.83%, a gap of +1.92%. The stock is currently −18.44% below its 52-week high, with maximum 3-year drawdown at −46.23%.
| Period | CVS | S&P 500 (SPY) | Excess return |
|---|---|---|---|
| 1 Day | −1.58% | +1.13% | −2.71% |
| 1 Week | −5.27% | +0.63% | −5.90% |
| 1 Month | −3.88% | −0.58% | −3.30% |
| 3 Months | −11.47% | +1.64% | −13.10% |
| 6 Months | +19.22% | +15.15% | +4.07% |
| YTD | +13.75% | +11.83% | +1.92% |
| 12 Months | +21.99% | +15.69% | +6.30% |
| 3 Years | +27.37% | +72.00% | −44.63% |
| Rank | Month | Return |
|---|---|---|
| #1 | Jan 2025 | +25.82% |
| #2 | Aug 2025 | +17.79% |
| #3 | Feb 2025 | +16.36% |
| #4 | Dec 2023 | +16.20% |
| #5 | Apr 2026 | +15.97% |
| Rank | Month | Return |
|---|---|---|
| #1 | Dec 2024 | −25.00% |
| #2 | Apr 2024 | −15.11% |
| #3 | Aug 2023 | −12.75% |
| #4 | May 2024 | −11.98% |
| #5 | Oct 2024 | −10.21% |
| Quarter | Return |
|---|---|
| Q2 2025 | +1.82% |
| Q3 2025 | +9.29% |
| Q4 2025 | +5.27% |
| Q1 2026 | −9.50% |
| Q2 2026 | +44.04% |
| Q3 2026 (QTD) | −12.74% |
| Year | Return |
|---|---|
| 2023 | −15.27% |
| 2024 | −43.15% |
| 2025 | +76.79% |
| 2026 | +13.75% |
| Metric | Value |
|---|---|
| 52-Week High | $110.68 (2026-07-22) |
| 52-Week Low | $69.51 (2026-03-30) |
| Current Price | $90.27 |
| 200-Day Moving Average | $86.79 |
| Price vs 200DMA | +4.01% |
| 3-Year Maximum Drawdown | −46.23% (2024-12-19) |
| Current Drawdown from 52W High | −18.44% |
| RS metric | Value |
|---|---|
| RS Index (3-year, rebased to 100) | 74.3 |
| 3-Year Excess Return vs S&P 500 | −44.63% |
| RS Peak | 109.2 (Jan 2024) |
| RS Trough | 45.7 (Dec 2024) |
| Status | Underperforming Benchmark |
Frequently asked questions
What was CVS's return for this report period?
CVS returned −3.88% in the latest monthly window ending 2026-09-17.
Has CVS outperformed SPY year to date?
YTD CVS: +13.75% vs SPY: +11.83%.
What is CVS's 12-month return?
+21.99% over the trailing 12 months.
Is CVS above or below its 200-day moving average?
Price is +4.01% versus 200DMA ($86.79).
What is the maximum drawdown in the 3-year window?
−46.23% on 2024-12-19.